Type of the measurement:
HbA1c The value of the HbA1c laboratory measurement. Covers values from both venous and capillary samples.
LDL The value of the LDL cholesterol laboratory measurement. Covers values from both fasting and non-fasting serum and plasma samples.
U-AlbCre The value of the U-AlbCre laboratory measurement, representing the ratio of albumin to creatinine concentration in a spot urine sample
eGFR The value of the Pt-GFReEPI laboratory measurement, i.e. the estimated glomerular filtration rate. The calculation is performed using the CKD-EPI equation, which requires plasma creatinine concentration, sex, and age.
Value of the measurement:
AlbKre: mg/mmol
GDF: ml/min/1,73m^2
HbA1c: mmol/mol
LDL: mmol/l
Is value of the measurement outlier?
0 = No1 = Yes (high)-1 = Yes (low)
| VARIABLE | DESCRIPTION | VALUES |
|---|---|---|
| FINNGENID | Studyid | |
| APPROX_DIAG_DATE | Randomized first diagnosis date (randomized +/- 1-15 days from the exact date). The date is the earliest recorded date of diabetes diagnosis. Selected as the earliest of the following: the date of the first diabetes diagnosis (ICD-10: E10–E14), the creation date of the diagnosis document, the date of the first diabetes prescription (ATC: A10), or the date of the first special reimbursement entitlement decision (codes 103, 215, 285, 295, 346, or 3022). | |
| EVENT_AGE | Age at the time of the first diagnosis | |
| APPROX_DEATH_DATE | Randomized death date (randomized +/- 1-15 days from the exact date) | |
| DMTYPE2 | Diabetes type. The patient's diabetes type (1, 2 or 4). Based on the patient's two most recent consecutive and concordant diabetes diagnoses. If no such pair is found, the patient's most recent diabetes diagnosis has been used instead. |
|
| MEDTYPEID2 | Diabetes medication type. The diabetes medication type based on medication purchases made during the patient's last year of life, derived from ATC codes |
See more detailed information in readme file. |
| HIRISK | Risk of atherosclerotic event. Indicates whether a patient has an elevated risk of cardiovascular events and death. |
See more detailed information in readme file. |
| KIDNEY_DISEASE | Risk of kidney disease progression. Describes the risk of kidney disease based on the patient's most recent U-AlbKre and eGFR (Pt-GFReEPI) measurements within the past 24 months. | 1 = Low risk: U-AlbKre lower than 3 and eGFR higher than 60,
2 = Moderate risk: (U-AlbKre 3–30 and eGFR higher than 60) or (U-AlbKre lower than 3 and eGFR 45–59),
3 = High risk: (U-AlbKre higher than 30 and eGFR higher than 60) or (U-AlbKre 3–30 and eGFR 30–59 or (U-AlbKre lower than 3 and eGFR 30–44),
4 = Very high risk: (eGFR lower than 29) or (U-AlbKre higher than 30 and eGFR lower than 60),
0 = no information
A null value indicates that the category could not be determined. |
| REIMBURSEMENT | Special reimbursement entitlement. The variable indicates which special reimbursement entitlements the patient has received (zero, one, or more). Bits 1–6 of this integer variable correspond to the following special reimbursement codes:
Bit number = Special reimbursement code | 1 = 103 (diabetes, insulin therapy)
2 = 215 (diabetes, treatment other than insulin)
3 = 285 (dulaglutide, exenatide, liraglutide and semaglutide, higher reimbursement category, type 2 diabetes, adults)
4 = 295 (liraglutide, higher reimbursement category, type 2 diabetes, children and adolescents)
5 = 346 (dulaglutide, exenatide, liraglutide and semaglutide, basic/lower reimbursement category, type 2 diabetes, adults)
6 = 3022 (liraglutide, basic/lower special reimbursement, type 2 diabetes, children and adolescents)
0 = no special reimbursement entitlements |